{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:35:40Z","timestamp":1789623340638,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-024-10412-y","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T01:05:01Z","timestamp":1719882301000},"page":"949-955","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2223-7215","authenticated-orcid":false,"given":"Satoshi","family":"Shoji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"key":"10412_CR1","volume-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000001063"},{"key":"10412_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"10412_CR3","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O et al (2022) Safety, tolerability, and efficacy of up-titration of guideline- directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400:1938\u20131952. https:\/\/doi.org\/10.1016\/S0140-6736(22)02076-1","journal-title":"Lancet"},{"key":"10412_CR4","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehad195","volume":"37","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M et al (2023) 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129\u20132200.\u00a0https:\/\/doi.org\/10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"},{"key":"10412_CR5","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1161\/CIRCULATIONAHA.115.018094","volume":"133","author":"MA Psotka","year":"2016","unstructured":"Psotka MA, Teerlink JR (2016) Ivabradine: role in the chronic heart failure armamentarium. Circulation 133:2066\u20132075. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018094","journal-title":"Circulation"},{"key":"10412_CR6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875\u2013885. https:\/\/doi.org\/10.1016\/S0140-6736(10)61198-1","journal-title":"Lancet"},{"key":"10412_CR7","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1161\/01.cir.94.11.2807","volume":"94","author":"MR Bristow","year":"1996","unstructured":"Bristow MR, Gilbert EM, Abraham WT et al (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure.\u00a0MOCHA Investigators. Circulation 94:2807\u20132816. https:\/\/doi.org\/10.1161\/01.cir.94.11.2807","journal-title":"Circulation"},{"key":"10412_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jacc.2012.03.023","volume":"60","author":"M Fiuzat","year":"2012","unstructured":"Fiuzat M, Wojdyla D, Kitzman D et al (2012) Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (heart failure: a controlled trial investigating outcomes of exercise training) trial. J Am Coll Cardiol 60:208\u2013215. https:\/\/doi.org\/10.1016\/j.jacc.2012.03.023","journal-title":"J Am Coll Cardiol"},{"key":"10412_CR9","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/ejhf.81","volume":"16","author":"R B\u00f8lling","year":"2014","unstructured":"B\u00f8lling R, Scheller NM, K\u00f8ber L et al (2014) Comparison of the clinical outcome of different beta-blockers in heart failure patients: a retrospective nationwide cohort study. Eur J Heart Fail 16:678\u2013684. https:\/\/doi.org\/10.1002\/ejhf.81","journal-title":"Eur J Heart Fail"},{"key":"10412_CR10","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","volume":"100","author":"RIR Martin","year":"2014","unstructured":"Martin RIR, Pogoryelova O, Koref MS et al (2014) Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart 100:1506\u20131510. https:\/\/doi.org\/10.1136\/heartjnl-2014-305482","journal-title":"Heart"},{"key":"10412_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/clc.22578","volume":"39","author":"\u0130H Tanbo\u011fa","year":"2016","unstructured":"Tanbo\u011fa \u0130H, Top\u00e7u S, Aksakal E et al (2016) The risk of atrial fibrillation with ivabradine treatment: a meta-analysis with trial sequential analysis of more than 40000 patients. Clin Cardiol 39:615\u2013620. https:\/\/doi.org\/10.1002\/clc.22578","journal-title":"Clin Cardiol"},{"key":"10412_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/nejmoa1406430","volume":"371","author":"K Fox","year":"2014","unstructured":"Fox K, Ford I, Steg PG et al (2014) Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 371:1091\u20131099. https:\/\/doi.org\/10.1056\/nejmoa1406430","journal-title":"N Engl J Med"},{"key":"10412_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s10557-020-07124-4","volume":"35","author":"C Chen","year":"2021","unstructured":"Chen C, Kaur G, Mehta PK et al (2021) Ivabradine in cardiovascular disease management revisited: a review. Cardiovasc Drugs Ther 35:1045\u20131056. https:\/\/doi.org\/10.1007\/s10557-020-07124-4","journal-title":"Cardiovasc Drugs Ther"},{"key":"10412_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/2040622318784556","volume":"9","author":"C Badu-Boateng","year":"2018","unstructured":"Badu-Boateng C, Jennings R, Hammersley D (2018) The therapeutic role of ivabradine in heart failure. Ther Adv Chronic Dis 9:199\u2013207. https:\/\/doi.org\/10.1177\/2040622318784556","journal-title":"Ther Adv Chronic Dis"},{"key":"10412_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003221","author":"AR Kansal","year":"2016","unstructured":"Kansal AR, Cowie MR, Kielhorn A et al (2016) Cost-effectiveness of ivabradine for heart failure in the United States. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.116.003221","journal-title":"J Am Heart Assoc"},{"key":"10412_CR16","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1136\/heartjnl-2013-304598","volume":"100","author":"A Griffiths","year":"2014","unstructured":"Griffiths A, Paracha N, Davies A et al (2014) The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K.\u00a0National Health Service perspective. Heart 100:1031\u20131036. https:\/\/doi.org\/10.1136\/heartjnl-2013-304598","journal-title":"Heart"},{"key":"10412_CR17","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.hlc.2018.01.011","volume":"28","author":"MA Adena","year":"2019","unstructured":"Adena MA, Hamann G, Sindone AP (2019) Cost-effectiveness of ivabradine in the treatment of chronic heart failure. Heart Lung Circ 28:414\u2013422. https:\/\/doi.org\/10.1016\/j.hlc.2018.01.011","journal-title":"Heart Lung Circ"},{"key":"10412_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tsch\u00f6pe C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62:263\u2013271. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.092","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"10412_CR19","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","volume":"122","author":"P Sandner","year":"2017","unstructured":"Sandner P, Stasch JP (2017) Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Respir Med 122(Suppl):S1\u2013S9. https:\/\/doi.org\/10.1016\/j.rmed.2016.08.022","journal-title":"Respir Med"},{"key":"10412_CR20","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","volume":"123","author":"JP Stasch","year":"2011","unstructured":"Stasch JP, Pacher P, Evgenov OV (2011) Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123:2263\u20132273. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.981738","journal-title":"Circulation"},{"key":"10412_CR21","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10741-021-10146-1","volume":"27","author":"A Aimo","year":"2022","unstructured":"Aimo A, Castiglione V, Vergaro G et al (2022) The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Fail Rev 27:1165\u20131171. https:\/\/doi.org\/10.1007\/s10741-021-10146-1","journal-title":"Heart Fail Rev"},{"key":"10412_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/CRD.0000000000000431","volume":"31","author":"R Gupta","year":"2023","unstructured":"Gupta R, Lin M, Maitz T et al (2023) Vericiguat: a novel soluble guanylate cyclase stimulator for use in patients with heart failure. Cardiol Rev 31:87\u201392. https:\/\/doi.org\/10.1097\/CRD.0000000000000431","journal-title":"Cardiol Rev"},{"key":"10412_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","volume":"6","author":"PW Armstrong","year":"2018","unstructured":"Armstrong PW, Roessig L, Patel MJ et al (2018) A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial. JACC Heart Fail 6:96\u2013104. https:\/\/doi.org\/10.1016\/j.jchf.2017.08.013","journal-title":"JACC Heart Fail"},{"key":"10412_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915928","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa1915928","journal-title":"N Engl J Med"},{"key":"10412_CR25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/eurheartj\/ehz916","volume":"42","author":"JJV McMurray","year":"2021","unstructured":"McMurray JJV, Solomon SD, Docherty KF, Jhund PS (2021) The dapagliflozin and prevention of adverse outcomes in heart failure trial (DAPA-HF) in context. Eur Heart J 42:1199\u20131202. https:\/\/doi.org\/10.1093\/eurheartj\/ehz916","journal-title":"Eur Heart J"},{"key":"10412_CR26","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"10412_CR27","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"10412_CR28","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/ejhf.1664","volume":"21","author":"B Pieske","year":"2019","unstructured":"Pieske B, Patel MJ, Westerhout CM et al (2019) Baseline features of the VICTORIA (vericiguat global study in subjects with heart failure with reduced ejection fraction) trial. Eur J Heart Fail 21:1596\u20131604. https:\/\/doi.org\/10.1002\/ejhf.1664","journal-title":"Eur J Heart Fail"},{"key":"10412_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.12.005","author":"RJ Mentz","year":"2024","unstructured":"Mentz RJ, Stebbins A, Butler J et al (2024) Recurrent hospitalizations and response to vericiguat in heart failure and reduced ejection fraction. JACC Heart Fail. https:\/\/doi.org\/10.1016\/j.jchf.2023.12.005","journal-title":"JACC Heart Fail"},{"key":"10412_CR30","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/ejhf.2221","volume":"23","author":"AA Voors","year":"2021","unstructured":"Voors AA, Mulder H, Reyes E et al (2021) Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (vericiguat global study in subjects with HFrEF) trial. Eur J Heart Fail 23:1313\u20131321. https:\/\/doi.org\/10.1002\/ejhf.2221","journal-title":"Eur J Heart Fail"},{"key":"10412_CR31","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","volume":"6","author":"CSP Lam","year":"2021","unstructured":"Lam CSP, Giczewska A, Sliwa K et al (2021) Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial. JAMA Cardiol 6:706\u2013712. https:\/\/doi.org\/10.1001\/jamacardio.2020.6455","journal-title":"JAMA Cardiol"},{"key":"10412_CR32","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","volume":"8","author":"JA Ezekowitz","year":"2020","unstructured":"Ezekowitz JA, O\u2019Connor CM, Troughton RW et al (2020) N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail 8:931\u2013939. https:\/\/doi.org\/10.1016\/j.jchf.2020.08.008","journal-title":"JACC Heart Fail"},{"key":"10412_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00176-5","volume":"8","author":"VJ Planelles-Herrero","year":"2017","unstructured":"Planelles-Herrero VJ, Hartman JJ, Robert-Paganin J et al (2017) Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat Commun 8:1\u201310. https:\/\/doi.org\/10.1038\/s41467-017-00176-5","journal-title":"Nat Commun"},{"key":"10412_CR34","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","volume":"388","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR, Felker GM, McMurray JJV et al (2016) Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 388:2895\u20132903. https:\/\/doi.org\/10.1016\/S0140-6736(16)32049-9","journal-title":"Lancet"},{"key":"10412_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/nejmoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink JR, Diaz R, Felker GM et al (2021) Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med 384:105\u2013116. https:\/\/doi.org\/10.1056\/nejmoa2025797","journal-title":"N Engl J Med"},{"key":"10412_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/jamacardio.2021.4027","volume":"7","author":"GM Felker","year":"2022","unstructured":"Felker GM, Solomon SD, Claggett B et al (2022) Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial. JAMA Cardiol 7:26\u201334. https:\/\/doi.org\/10.1001\/jamacardio.2021.4027","journal-title":"JAMA Cardiol"},{"key":"10412_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jacc.2021.04.065","volume":"78","author":"JR Teerlink","year":"2021","unstructured":"Teerlink JR, Diaz R, Felker GM et al (2021) Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF. J Am Coll Cardiol 78:97\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.065","journal-title":"J Am Coll Cardiol"},{"key":"10412_CR38","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1093\/eurheartj\/ehac293","volume":"43","author":"M Metra","year":"2022","unstructured":"Metra M, Pagnesi M, Claggett BL et al (2022) Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. Eur Heart J 43:5006\u20135016. https:\/\/doi.org\/10.1093\/eurheartj\/ehac293","journal-title":"Eur Heart J"},{"key":"10412_CR39","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/ejhf.1557","volume":"21","author":"T Ahmad","year":"2019","unstructured":"Ahmad T, Miller PE, McCullough M et al (2019) Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. Eur J Heart Fail 21:1064\u20131078. https:\/\/doi.org\/10.1002\/ejhf.1557","journal-title":"Eur J Heart Fail"},{"key":"10412_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jchf.2019.12.001","volume":"8","author":"JR Teerlink","year":"2020","unstructured":"Teerlink JR, Diaz R, Felker GM et al (2020) Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC Heart Fail 8:329\u2013340. https:\/\/doi.org\/10.1016\/j.jchf.2019.12.001","journal-title":"JACC Heart Fail"},{"key":"10412_CR41","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1126\/science.1200113","volume":"331","author":"FI Malik","year":"2011","unstructured":"Malik FI, Hartman JJ, Elias KA et al (2011) Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (80-) 331:1439\u20131443. https:\/\/doi.org\/10.1126\/science.1200113","journal-title":"Science (80-)"},{"key":"10412_CR42","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.amjcard.2023.08.013","volume":"205","author":"J Harrington","year":"2023","unstructured":"Harrington J, Sun JL, Fonarow GC et al (2023) Potential applicability of omecamtiv mecarbil to patients hospitalized for worsening heart failure. Am J Cardiol 205:524\u2013526. https:\/\/doi.org\/10.1016\/j.amjcard.2023.08.013","journal-title":"Am J Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10412-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10412-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10412-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T08:22:38Z","timestamp":1723018958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10412-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["10412"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10412-y","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,29]]},"assertion":[{"value":"17 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Mentz has received research support and\/or honoraria from Novartis, Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Eli Lilly, Medtronic, Medable, Merck, Novo Nordisk, Pharmacosmos, Relypsa, Respicardia, Roche, Sanofi, Vifor, Windtree Therapeutics, and Zoll.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}